PDS Biotechnology Corp Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
PDS Biotechnology Corp (PDSB) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$21.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- PDS Biotechnology Corp cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$5.05M.
- PDS Biotechnology Corp cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$1.71M, a 116.98% decline year-over-year.
- PDS Biotechnology Corp cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $10.07M.
- PDS Biotechnology Corp cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$8.62M.
- PDS Biotechnology Corp cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$14.98M.
- PDS Biotechnology Corp cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$14.87M.
- PDS Biotechnology Corp cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$17.26M, a 301.22% decline from fiscal 2022.
- PDS Biotechnology Corp cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $8.58M, a 76.44% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$21.12M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$5.05M 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | -$14.98M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | -$15.49M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$9.82M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$1.71M 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | -$14.87M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | -$6.81M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $1.17M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $10.07M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$17.26M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$19.57M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$13.20M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$8.62M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $8.58M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $6.40M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$12.26M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$6.36M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $36.40M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $40.90M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $45.91M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$3.80M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $16.68M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $21.31M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $4.77M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $8.88M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $12.06M 10-K · filed 2021-03-18 | |||
| 2019-09-30 | $17.30M 10-Q · filed 2020-11-13 | |||
| 2019-06-30 | $21.63M 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | $26.49M 10-Q · filed 2020-05-13 | |||
| 2018-12-31 | -$72.19K 10-K · filed 2020-03-27 | |||
| 2018-09-30 | -$33.22K 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $229.28K 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | $648.18K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |